Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects

BACKGROUND: Inadequate platelet inhibition despite aspirin and clopidogrel therapy during and after a percutaneous coronary intervention is associated with an impaired clinical outcome. Cangrelor, a direct and reversible P2Y(12) inhibitor that is currently in development, has the potential to achiev...

Full description

Saved in:
Bibliographic Details
Main Authors: Bouman, H.J., van Werkum, J.W., Hackeng, C.M., Clappers, N., ten Berg, J.M.
Format: Artigo
Language:Inglês
Published: Bohn Stafleu van Loghum 2009
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2688017/
https://ncbi.nlm.nih.gov/pubmed/19484155
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items